University of Pennsylvania-prof. Wei Guo and prof. Serge Fuchs

University of Pennsylvania

The University of Pennsylvania (Penn or UPenn) is a private Ivy League research university in Philadelphia, Pennsylvania. Founded nearly 300 years ago, it is one of the oldest institution of higher education in the United States. The University of Pennsylvania is ranked 11th university by the World University Rankings 2020 for its excellence in research, citations and teaching. It is also 4th university in US Rankings 2020. With more than $1.02 billion in annual R&D expenditures, Penn is one of the top research universities in the US. It consists of 165 Institutes/Schools/Research Centers. Within the EVIONA project, we are going to develop a collaboration with two outstanding research schools at Penn - School of Arts & Sciences and School of Veterinary Medicine.

 

Prof. Wei Guo

 

Research interest

  • interplay between secretion and the cytoskeleton
  • role of the exocyst in exocytosis, morphogenesis and cell migration in yeast and mammalian cells
  • molecular mechanisms of exosome biogenesis and secretion
  • role of EVs in cancer development, metastasis and immunosuppression

Wei Guo is Professor of Biology in the Department of Biology, School of Arts & Sciences Penn. Prof. Guo’s laboratory focuses on the molecular mechanisms of exocytic trafficking, including the biogenesis and secretion of extracellular vesicles (mainly exosomes). His research group aims to address three fundamental questions in cell biology: what is the molecular basis for exocytosis; how do the secretory machinery functions in concert with cytoskeleton and small-GTP-binding proteins during cell migration; how the basic cell biological processes, including the secretion of exosomes, are implicated in diseases such as cancer.

Taking a multidisciplinary approach that combines biochemistry, biophysics, genetics, and advanced microscopic imaging, his laboratory has made fundamental discoveries that contributed to the understanding of complicated interactions between tumor-derived exosomes and the tumor microenviroment and immune cells, which often leads to immunosuppression, cancer progression and metastasis. The results of this research have been published in prestigious journals (Chen et al 2018 Nature; Mei et al 2018 Nature Structural and Molecular Biology; Lu et al., 2017 Nature; Yue et al., 2017 Nature Communications; Lu et al., 2016 Cell Reports).

In 2018 the group has published its ground-braking work in Nature about melanoma cells secreting exosomes that contain the immunosuppressive PD-L1 molecules. The researchers have shown for the first time that the level of circulating exosomal PD-l1 is changing during anti-PD-1 immunotherapy and can be a predictor of therapy response, and stratifies clinical responders from non-responders among melanoma patients (https://penntoday.upenn.edu/news/cancer-cells-send-out-drones-battle-immune-system-afar)

Biography

Wei Guo obtained his PhD from University of Iowa College of Medicine and performed his postdoc training at Yale University. For his excellence in research and teaching he has received the following awards:

  • Pew Scholar in Biomedical Sciences
  • American Cancer Society Research Scholar
  • American Heart Association Established Investigator Award
  • Biology Department Teaching Award

Publications (last 10 years)

  • Mao L, Zhan YY, Wu B, Yu Q, Xu L, Hong X, Zhong L, Mi P, Xiao L, Wang X, et al.: ULK1 phosphorylates Exo70 to suppress breast cancer metastasis. Nat Commun 2020, 11:117.
  • Zhu Y, Wu B, Guo W: The role of Exo70 in exocytosis and beyond. Small GTPases 2019, 10:331-335.
  • Ortiz A, Gui J, Zahedi F, Yu P, Cho C, Bhattacharya S, Carbone CJ, Yu Q, Katlinski KV, Katlinskaya YV, et al.: An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles. Cancer Cell 2019, 35:33-45 e36.
  • Mei K, Yue P, Guo W: Analysis of the Role of Sec3 in SNARE Assembly and Membrane Fusion. Methods Mol Biol 2019, 1860:175-189.
  • Mei K, Guo W: Exocytosis: A New Exocyst Movie. Curr Biol 2019, 29:R30-R32.
  • Mandal K, Aroush DR, Graber ZT, Wu B, Park CY, Fredberg JJ, Guo W, Baumgart T, Janmey PA: Correction to Soft Hyaluronic Gels Promote Cell Spreading, Stress Fibers, Focal Adhesion, and Membrane Tension by Phosphoinositide Signaling, Not Traction Force. ACS Nano 2019, 13:4854.
  • Liu S, Zhang G, Guo J, Chen X, Lei J, Ze K, Dong L, Dai X, Gao Y, Song D, et al.: Author Correction: Loss of Phd2 cooperates with BRAF(V600E) to drive melanomagenesis. Nat Commun 2019, 10:1211.
  • Huang L, Li X, Li Y, Yin X, Li Y, Wu B, Mo H, Liao CJ, Mengiste T, Guo W, et al.: Endosidin2-14 Targets the Exocyst Complex in Plants and Fungal Pathogens to Inhibit Exocytosis. Plant Physiol 2019, 180:1756-1770.
  • Mei K, Li Y, Wang S, Shao G, Wang J, Ding Y, Luo G, Yue P, Liu JJ, Wang X, et al.: Cryo-EM structure of the exocyst complex. Nat Struct Mol Biol 2018, 25:139-146.
  • Mei K, Guo W: The exocyst complex. Curr Biol 2018, 28:R922-R925.
  • Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, et al.: Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 2018, 560:382-386.
  • Yue P, Zhang Y, Mei K, Wang S, Lesigang J, Zhu Y, Dong G, Guo W: Sec3 promotes the initial binary t-SNARE complex assembly and membrane fusion. Nat Commun 2017, 8:14236.
  • Lu H, Liu S, Zhang G, Bin W, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, et al.: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature 2017, 550:133-136.
  • Guo W, Liu X, Liu Y, Gang Y, He X, Jia Y, Yin F, Li P, Huang F, Zhou H, et al.: Chemical reactivation of resin-embedded pHuji adds red for simultaneous two-color imaging with EGFP. Biomed Opt Express 2017, 8:3281-3288.
  • Zhang C, Brown MQ, van de Ven W, Zhang ZM, Wu B, Young MC, Synek L, Borchardt D, Harrison R, Pan S, et al.: Endosidin2 targets conserved exocyst complex subunit EXO70 to inhibit exocytosis. Proc Natl Acad Sci U S A 2016, 113:E41-50.
  • Lu H, Liu S, Zhang G, Kwong LN, Zhu Y, Miller JP, Hu Y, Zhong W, Zeng J, Wu L, et al.: Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Rep 2016, 15:2012-2024.
  • Wu B, Wang J, Zhao Y, Guo W: Biochemical analysis of Rabin8, the guanine nucleotide exchange factor for Rab8. Methods Cell Biol 2015, 130:59-68.
  • Wu B, Guo W: The Exocyst at a Glance. J Cell Sci 2015, 128:2957-2964.
  • Wang J, Ren J, Wu B, Feng S, Cai G, Tuluc F, Peranen J, Guo W: Activation of Rab8 guanine nucleotide exchange factor Rabin8 by ERK1/2 in response to EGF signaling. Proc Natl Acad Sci U S A 2015, 112:148-153.
  • Feng S, Wu B, Peranen J, Guo W: Kinetic activation of Rab8 guanine nucleotide exchange factor Rabin8 by Rab11. Methods Mol Biol 2015, 1298:99-106.
  • Yu S, Yehia G, Wang J, Stypulkowski E, Sakamori R, Jiang P, Hernandez-Enriquez B, Tran TS, Bonder EM, Guo W, et al.: Global ablation of the mouse Rab11a gene impairs early embryogenesis and matrix metalloproteinase secretion. J Biol Chem 2014, 289:32030-32043.
  • Yang R, Zheng Y, Li L, Liu S, Burrows M, Wei Z, Nace A, Herlyn M, Cui R, Guo W, et al.: Direct conversion of mouse and human fibroblasts to functional melanocytes by defined factors. Nat Commun 2014, 5:5807.
  • Yang R, Zheng Y, Burrows M, Liu S, Wei Z, Nace A, Guo W, Kumar S, Cotsarelis G, Xu X: Generation of folliculogenic human epithelial stem cells from induced pluripotent stem cells. Nat Commun 2014, 5:3071.
  • Luo G, Zhang J, Guo W: The role of Sec3p in secretory vesicle targeting and exocyst complex assembly. Mol Biol Cell 2014, 25:3813-3822.
  • Das A, Gajendra S, Falenta K, Oudin MJ, Peschard P, Feng S, Wu B, Marshall CJ, Doherty P, Guo W, et al.: RalA promotes a direct exocyst-Par6 interaction to regulate polarity in neuronal development. J Cell Sci 2014, 127:686-699.
  • Zhao Y, Liu J, Yang C, Capraro BR, Baumgart T, Bradley RP, Ramakrishnan N, Xu X, Radhakrishnan R, Svitkina T, et al.: Exo70 generates membrane curvature for morphogenesis and cell migration. Dev Cell 2013, 26:266-278.
  • Luo G, Zhang J, Luca FC, Guo W: Mitotic phosphorylation of Exo84 disrupts exocyst assembly and arrests cell growth. J Cell Biol 2013, 202:97-111.
  • Lu H, Liu J, Liu S, Zeng J, Ding D, Carstens RP, Cong Y, Xu X, Guo W: Exo70 isoform switching upon epithelial-mesenchymal transition mediates cancer cell invasion. Dev Cell 2013, 27:560-573.
  • Cai B, Giridharan SS, Zhang J, Saxena S, Bahl K, Schmidt JA, Sorgen PL, Guo W, Naslavsky N, Caplan S: Differential roles of C-terminal Eps15 homology domain proteins as vesiculators and tubulators of recycling endosomes. J Biol Chem 2013, 288:30172-30180.
  • Wang Z, Fayngerts S, Wang P, Sun H, Johnson DS, Ruan Q, Guo W, Chen YH: TIPE2 protein serves as a negative regulator of phagocytosis and oxidative burst during infection. Proc Natl Acad Sci U S A 2012, 109:15413-15418.
  • Sakamori R, Das S, Yu S, Feng S, Stypulkowski E, Guan Y, Douard V, Tang W, Ferraris RP, Harada A, et al.: Cdc42 and Rab8a are critical for intestinal stem cell division, survival, and differentiation in mice. J Clin Invest 2012, 122:1052-1065.
  • Ren J, Guo W: ERK1/2 regulate exocytosis through direct phosphorylation of the exocyst component Exo70. Dev Cell 2012, 22:967-978.
  • Liu S, Kumar SM, Lu H, Liu A, Yang R, Pushparajan A, Guo W, Xu X: MicroRNA-9 up-regulates E-cadherin through inhibition of NF-kappaB1-Snail1 pathway in melanoma. J Pathol 2012, 226:61-72.
  • Liu J, Zhao Y, Sun Y, He B, Yang C, Svitkina T, Goldman YE, Guo W: Exo70 stimulates the Arp2/3 complex for lamellipodia formation and directional cell migration. Curr Biol 2012, 22:1510-1515.
  • Liu J, Guo W: The exocyst complex in exocytosis and cell migration. Protoplasma 2012, 249:587-597.
  • Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ, Gimotty PA, Guerra M, Guo W, Xu X: Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene 2012, 31:4898-4911.
  • Feng S, Knodler A, Ren J, Zhang J, Zhang X, Hong Y, Huang S, Peranen J, Guo W: A Rab8 guanine nucleotide exchange factor-effector interaction network regulates primary ciliogenesis. J Biol Chem 2012, 287:15602-15609.
  • Orlando K, Sun X, Zhang J, Lu T, Yokomizo L, Wang P, Guo W: Exo-endocytic trafficking and the septin-based diffusion barrier are required for the maintenance of Cdc42p polarization during budding yeast asymmetric growth. Mol Biol Cell 2011, 22:624-633.
  • Das A, Guo W: Rabs and the exocyst in ciliogenesis, tubulogenesis and beyond. Trends Cell Biol 2011, 21:383-386.
  • Warzecha CC, Jiang P, Amirikian K, Dittmar KA, Lu H, Shen S, Guo W, Xing Y, Carstens RP: An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO J 2010, 29:3286-3300.
  • Knodler A, Feng S, Zhang J, Zhang X, Das A, Peranen J, Guo W: Coordination of Rab8 and Rab11 in primary ciliogenesis. Proc Natl Acad Sci U S A 2010, 107:6346-6351.
  • Baek K, Knodler A, Lee SH, Zhang X, Orlando K, Zhang J, Foskett TJ, Guo W, Dominguez R: Structure-function study of the N-terminal domain of exocyst subunit Sec3. J Biol Chem 2010, 285:10424-10433.

 

 

 

School of Veterinary Medicine at the University of Pennsylvania

 

The School of Veterinary Medicine at the University of Pennsylvania (Penn Vet) was founded in 1884, and has a long-standing tradition as a global leader in veterinary medicine education, research, and clinical care. The Penn Vet faculty conducts research in molecular and cellular biology, translational research and clinical trials, including groundbreaking biomedical research projects in comparative oncology, molecular genetics, stem cell biology, parasite immunology, clinical and basic neuroscience. The Penn's School of Veterinary Medicine has variety of core facilities, including Extracellular Vesicle (EV) Core Facility providing comprehensive or selected services in isolation, quantification and characterization of EVs.  

The numerous Research Centers of Penn Vet's focus on:

  • comparative oncology
  • infectious diseases
  • regenerative medicine
  • health and productivity in food animal herds and flocks
  • neuroscience

The mission of Mari Lowe Center for Comparative Oncology Research (MLCCO, established in 1994) is to develop a multidisciplinary program in oncology, including basic, translational, and clinical research as well as training programs in oncology. In order to develop diagnostic and treatment modalities beneficial to both animal and human patients MLCCO exploits small animal spontaneous tumor models.

 

 

 

Prof. Serge Fuchs

 

 

 

Research interest

  • Cancer development, progression and metastasis
  • Inflammation and stress in the tumor microenvironment
  • Aberrations of cytokine and growth factors receptors in cancer

The research of Prof. Fuchs group is focused on the regulation of intercellular signaling, initiated by cytokines and growth factors, leading to transcriptional regulation. The ubiquitination of cytokine and growth factor receptors is part of “eliminative signaling” which leads to downregulation of receptors and cell de-sensitization. The laboratory of Prof. Fuchs identifies the aberrations in eliminative signaling of cytokine/growth factor receptors that are critical to development of cancers, autoimmune diseases and responses to infections. The interferon alpha receptor (IFNAR) is one of such receptors.  Its ligand, type I IFN, is often used in therapy of cancers, chronic viral infections and multiple sclerosis. Therefore new potential regulators of IFNAR signaling can be used to increase the efficacy of IFN against cancers and chronic viral infections or to prevent harmful effects of IFN in pathogenesis of autoimmune diseases. 

Following this idea the research team of Prof. Fuchs focused recently on Tumor-derived extracellular vesicles (TEV). In collaboration with other research groups they found that TEVs from melanoma downregulated type I interferon (IFN) receptor and ‘‘educated’’ healthy cells to promote metastases. Importantly, in the mouse model of melanoma the anti-hypertensive drug, reserpine, suppressed TEV uptake and disrupted TEV-induced formation of the pre-metastatic niche and melanoma lung metastases (Ortiz et al., Cancer Cell 2019).

Biography

Serge Fuchs obtained his MD degree from the Yaroslavl State Medical Institute in Russia followed by PhD degree in Experimental Oncology from the All-Union Cancer Research Center in Russia and postdoctoral training in Molecular Carcinogenesis Program of American Health Foundation (Valhalla, NY, USA). Currently Prof. Fuchs is the Elizabeth and William Whitney Clark Professor of Oncology at the Dept. of Biomedical Sciences, University of Pennsylvania.

Research team members

  • Ms. Ann DeVine   
  • Dr. Hongru Zhang   
  • Dr. Christina Cho          
  • Dr. Noreen McBrearty       
  • Dr. Vivek Tomar           
  • Dr. Zhen Lu                  
  • Dr. Jinyun Chen           

Publications (last 10 years)

  • Odnokoz O, Yu P, Peck AR, Sun Y, Kovatich AJ, Hooke JA, Hu H, Mitchell EP, Rui H, and Fuchs SY (2020) Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers. Cancer Biol Ther, in press
  • Gui J, Zahedi F, Ortiz A, Cho C, Katlinski KV, Alicea-Torres K, Li J, Todd L, Zhang H, Beiting DP, Sander C, Kirkwood JM, Snow BE, Wakeham AC, Mak TW, Diehl JA, Koumenis C, Ryeom SW, Stanger BZ, Puré E, Gabrilovich DI, and Fuchs SY (2020) Activation of p38α stress-activated protein kinase drives the formation of the pre-metastatic niche in the lungs. Nat Cancer, in press
  • Ardanuy J, Skerry C, Scanlon K, Fuchs SY and Carbonetti NH (2020) Age-dependent effects of type I and type III interferons in the pathogenesis of Bordetella pertussis infection and disease. J Immunol, in press
  • Singh S, Kumar S, Srivastava RK, Nandi A, Thacker G, Murali H, Kim S, Baldeon M, Tobias J, Blanco MA, Saffie R, Zaidi MR, Sinha S, Busino L, Fuchs SY and Chakrabarti R (2020) Loss of ELF5/FBXW7 stabilises IFNGR1 to promote growth and metastasis of triple negative breast cancer through interferon-γ signalling. Nat Cell Biol, in press
  • Ortiz A, Gui J, Zahedi F, Yu P, Cho C, Bhattacharya S, Carbone CJ, Yu Q, Katlinski KV, Katlinskaya YV, Handa S, Haas V, Volk SW, Brice AK, Wals K, Matheson NJ, Antrobus R, Ludwig S, Whiteside TL, Sander C, Tarhini AA, Kirkwood JM, Lehner PJ, Guo W, Rui, H, Minn AJ, Koumenis C, Diehl JA and Fuchs SY (2019) An interferon-driven oxysterol-based defense against tumor-derived extracellular vesicles. Cancer Cell, 35: 33-45.
  • Kumar S, Srivastav RK, Wilkes DW, Ross T, Kim S, Kowalski J, Chatla S, Zhang Q, Nayak A, Guha M, Fuchs SY, Thomas C, and Chakrabarti R (2019) Estrogen dependent DLL1-mediated Notch signaling promotes luminal breast cancer. Oncogene, 38: 2092-2107.
  • Angireddy R, Kazmi HR, Srinivasan S, Sun L, Iqbal J, Fuchs SY, Guha M, Kijima T, Yuen T, Zaidi M, and Avadhani NG (2019) Cytochrome c oxidase dysfunction enhances phagocytic function and osteoclast formation in macrophages. FASEB J, 33: 9167-9181.
  • Gui J, Katlinski KV, Koumenis C, Diehl JA and Fuchs SY (2019) The PKR-like endoplasmic reticulum kinase promotes the dissemination of Myc-induced leukemic cells. Mol Cancer Res, 17: 1450-1458.
  • Tameire F, Verginadis II, Leli NM, Polte C, Conn CS, Ojha R, Salas C, Chinga F, Monroy AM, Fu W, Wang P, Kossenkov A, Ye J, Amaravadi RK, Ignatova Z, Fuchs SY, Diehl JA, Ruggero D, and Koumenis C (2019) ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression. Nat Cell Biol, 21: 889-899.
  • Bradley KC, Finsterbusch K, Schnepf D, Crotta S, Sopena ML, Davidson S, Fuchs SY, Staeheli P, and Wack A (2019) Microbiota-Driven Tonic Interferon Signals in Lung Stromal Cells Protect from Influenza Virus Infection. Cell Rep, 28: 245-256.
  • Bu Y, Yoshida A, Chitnis N, Altman B, Taylor A, Gennaro V, Armeson KE, McMahon S, Dang CV, Ruggero D, Koumenis C, Fuchs SY, and Diehl JA (2018) A PERK-miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival. Nat Cell Biol, 20: 104-115.
  • Zhao B, Bhattacharya S, Yu Q, and Fuchs SY (2018) Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia. Leuk Lymphoma, 59: 171-177.
  • Ghosh J, Roy Chowdhury A, Srinivasan S, Chattopadhyay M, Bose M, Bhattacharya S, Raza H, Fuchs SY, Rustgi AK, Gonzalez FJ, and Avadhani NG (2018) Cigarette Smoke Toxins-induced mitochondrial dysfunction and pancreatitis involves Aryl hydrocarbon receptor mediated Cyp1 gene expression: protective effects of resveratrol. Toxicol Sci, 166: 428-440.
  • Chowdhury AR, Long A, Fuchs SY, Rustgi A and Avadhani NG (2017) Mitochondrial stress-induced p53 attenuates HIF-1α activity by physical association and enhanced ubiquitination. Oncogene, 36: 397-409.
  • Zhang KJ, Yin XF, Yang YQ, Li HL, Xu YN, Chen LY, Liu XJ, Yuan SJ, Fang XL, Xiao J, Wu S, Xu HN, Chu L, Katlinski KV, Katlinskaya YV, Guo RB, Wei GW, Wang DC, Liu XY, and Fuchs SY (2017) A potent in vivo anti-tumor efficacy of novel recombinant type I interferon. Clin Cancer Res, 23: 2038-2049.
  • Katlinski KV, Gui J, Katlinskaya KV, Ortiz A, Chakraborty R, Bhattacharya S, Carbone CC, Beiting DP, Girondo MA, Peck AR, Puré E, Chatterji P, Rustgi AK, Diehl JA, Koumenis C, Rui H and Fuchs SY (2017) Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment. Cancer Cell, 31: 194-207.
  • Gui J, Lyu K, Tong W, and Fuchs SY (2017) Downregulation of the IFNAR1 chain of type 1 interferon receptor contributes to the maintenance of the hematopoietic stem cells. Cancer Biol Ther, 18: 534-543.
  • Katlinskaya YV, Katlinski KV, Lasri A, Li N, Beiting DP, Durham AC, Yang T, Pikarsky E, Lengner CJ, Johnson FB Ben-Neriah Y, and Fuchs SY (2016) Type 1 interferons control proliferation and function of intestinal epithelium. Mol Cell Biol, 36: 1124-35.
  • Katlinskaya YV, Katlinski KV, Yu Q, Ortiz A, Beiting DP, Brice A, Davar D, Sanders C, Kirkwood JM, Rui H, Xu X, Koumenis C, Diehl JA and Fuchs SY (2016) Suppression of type I interferon signaling overcomes oncogene-induced senescence and mediates melanoma development and progression. Cell Rep, 15: 171-180.
  • Xu Z, Bu Y, Chitnis N, Koumenis C, Fuchs SY and Diehl JA (2016) miR-216b-dependent regulation of c-Jun mediates GADD153/CHOP-dependent apoptosis. Nature Commun, 7:11422.
  • Gui J, Gober M, Xiaoping Y, Katlinski KV, Marshall CM, Sharma M, Werth VP, Baker DP, Rui H, Seykora JT and Fuchs SY (2016) Therapeutic elimination of the type 1 interferon receptor for treating psoriatic skin inflammation. J Invest Dermatol, 136: 1990-2002.
  • Pytel D, Gao Y, Mackiewicz K, Katlinskaya YV, Staschke K, Paredes M, Yoshida A, Qie S, Zhang G, Chajewski O, Wu L, Majsterek I, Herlyn M, Fuchs SY and Diehl JA (2016) Gene dose determines tumor-suppressive versus tumor promoting properties of PERK in melanoma. PLoS Genet, 12: e1006518.
  • Yu Q, Carbone CJ, Katlinskaya YV, Zheng H, Zheng K, Luo M, Wang PJ, Greenberg RA and Fuchs SY (2015) Type I interferon controls propagation of Long Interspersed Element-1. J Biol Chem, 290: 10191-9.
  • Yu Q, Katlinskaya YV, Carbone CJ, Zhao B, Katlinski KV, Zheng H, Guha M, Li N, Chen Q, Yang T, Lengner CJ, Greenberg RA, Johnson FB, and Fuchs SY (2015) DNA damage-induced type I interferon promotes senescence and inhibits stem cell function. Cell Rep, 11: 785-97.
  • Dey S, Sayers CM, Verginadis II, Lehman SL, Cheng Y, Cerniglia GJ, Tuttle SW, Feldman MD, Zhang PJL, Fuchs SY, Diehl JA, and Koumenis C (2015) ATF4-dependent induction of heme oxygenase 1 prevents anoikis and promotes metastasis. J Clin Invest, 125: 2592-608.
  • Katlinskaya Y, Carbone CJ, Yu Q and Fuchs SY (2015) Type 1 interferons contribute to the clearance of senescent cells. Cancer Biol Ther, 16: 1214-9.
  • Yu Q, Zhao B, Katlinski KV, Brice A, Gao Y, Li C, Kushner JA, Koumenis C, Diehl JA, and Fuchs SY (2015) Type I interferons mediate pancreatic toxicities of PERK inhibition. Proc Natl Acad Sci USA, 112: 15420-5.
  • Xia C, Vijayan M, Pritzl CJ, Fuchs SY, McDermott AB, and Hahm B (2015) Hemagglutinin of influenza 1 A virus antagonizes type I IFN responses by inducing degradation of type I IFN receptor 1. J Virol, 90: 2403-17.
  • Chandra PK, Bao L, Song K, Aboulnasr FM, Baker DP, Shores N, Wimley WC, Liu S, Hagedorn CH, Fuchs SY, Wu T, Balart LA and Dash S (2014) HCV infection selectively impairs Type I but not the Type III IFN signaling. Am J Pathol, 184: 214-229.
  • Sato T, Tran TH, Peck AR, Girondo MA, Liu C, Goodman CR, Neilson LM, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Fuchs SY, and Rui H (2014) Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression. Oncogene, 33: 2215-24
  • Bhattacharya S, Katlinski KV, Reichert M, Takano S, Brice A, Zhao B, Yu Q, Zheng H, Carbone CJ, Katlinskaya YV, Leu NA, McCorkell KA, Srinivasan S, Girondo M, Rui H, May MJ, Avadhani NG, Rustgi AK, and Fuchs SY (2014) Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury. Embo Mol Med, 6: 384-97.
  • Thom CS, Traxler EA, Khandros E, Nickas JM, Zhou OY, Lazarus JE, Silva APG, Prabhu D, Yao Y, Aribeana C, Fuchs SY, Mackay JP, Holzbaur ELF and Weiss MJ (2014) Trim58 degrades dynein and regulates terminal erythropoiesis. Dev Cell, 30: 688-700.
  • Xu J, Sun D, Jiang J, Deng L, Zhang Y, Yu H, Bahl D, Langenheim JF, Chen WY, Fuchs SY, and Frank SJ (2013) The role of prolactin receptor in growth hormone signaling in breast cancer cells. Mol Endocrinol, 27: 266-79.
  • Bhattacharya S, HuangFu WC, Dong G, Qian J, Baker DP, Karar J, Koumenis C, Diehl JA, and Fuchs SY (2013) Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses. Oncogene, 32: 4214-21.
  • Zheng H, Gupta V, Patterson-Fortin JP, Bhattacharya S, Katlinski K, Wu J, Varghese B, Carbone CJ, Aressy B, Fuchs SY*, and Greenberg RA* (2013) A novel BRISC-SHMT complex deubiquitinates IFNAR1 and regulates interferon responses. Cell Rep, 5: 180-193. * Joint corresponding authors
  • HuangFu WC, Qian J, Liu C, Liu J, Lokshin AE, Baker DP, Rui H, and Fuchs SY (2012) Inflammatory signaling compromises cell responses to interferon alpha. Oncogene, 31: 161-17.
  • Cho IR, Oh M, Koh SS, Malilas W, Srisuttee R, Jhun BH, Pellegrini S, Fuchs SY, and Chung YH (2012) Hepatitis B virus X protein inhibits extracellular IFN-α-mediated signal transduction by downregulation of type I IFN receptor. Int J Mol Med, 29: 581-86.
  • Chitnis N, Bobrovnikova-Marjon E, Pant D, Pytel D, Zheng H, Maas N, Frederick B, Kushner JA, Chodosh L, Koumenis C, Fuchs SY and Diehl JA (2012) miR-211 is a pro-survival micro-RNA that regulates chop expression in a PERK-dependent manner. Mol Cell, 48: 353-64.
  • Hart LS, Cunningham JT, Datta T, Dey S, Tameire F, Lehman SL, Qiu B, Zhang H, Cerniglia G, Bi M, Li Y, Gao Y, Liu H, Li C, Maity A, Thomas-Tikhonenko A, Perl AE, Koong A, Fuchs SY, Diehl JA, Mills IG, Ruggero D, and Koumenis C (2012) Endoplasmic reticulum stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. J Clin Invest, 122: 4621-34.
  • Carbone CJ, Zheng H, Bhattacharya S, Lewis JR, Reiter AM, Henthorn PS, Zhang ZY, Baker DP, Ukkiramapandian R, Bence KK, and Fuchs SY (2012) Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for anti-viral therapies. Proc Natl Acad Sci USA, 109: 19226-31.
  • Bhattacharya S, Qian J, Tzimas C, Baker DP, Koumenis C, Diehl JA, and Fuchs SY (2011) Role of p38 protein kinase in the ligand-independent ubiquitination and downregulation of the IFNAR1 chain of Type I interferon receptor. J Biol Chem, 286: 22069-76.
  • Bhattacharya S, Zheng H, Tzimas C, Carrol M, Baker DP, and Fuchs SY (2011) Bcr-abl signals to desensitize chronic myeloid leukemia cells to interferon alpha via accelerating the degradation of its receptor. Blood, 118: 4179-87.
  • Qian J, Zheng H, HuangFu WC, Liu J, Carbone CJ, Leu NA, Baker DP, and Fuchs SY (2011) Pathogen recognition receptor signaling accelerates phosphorylation-dependent degradation of IFNAR1. PLoS Pathogens, 7: e1002065.
  • Zheng, H, Qian J, Carbone CJ, Leu NA, Baker, DP and Fuchs SY (2011) Vascular Endothelial Growth Factor-induced elimination of the Type 1 interferon receptor is required for efficient angiogenesis. Blood, 118: 4003-6.
  • Zheng, H, Qian J, Baker, DP and Fuchs SY (2011) Tyrosine phosphorylation of protein kinase D2 mediates the ligand-inducible elimination of the Type 1 interferon receptor. J Biol Chem, 286: 35733-41.
  • Zheng H, Qian J, Varghese B, Baker DP and Fuchs S (2011) Ligand-stimulated downregulation of the interferon alpha receptor: role of protein kinase D2. Mol Cell Biol, 31: 710-20.
  • Varghese B, Swaminathan G, Plotnikov A, Tzimas C, Yang N, Rui H, and Fuchs SY (2010) Prolactin inhibits activity of pyruvate kinase M2 to stimulate cell proliferation. Mol Endocrinol, 24: 2356-65.
  • HuangFu WC, Qian J, Liu C, Rui H, and Fuchs SY (2010) Melanoma cell-secreted soluble factor that stimulates ubiquitination and degradation of the interferon alpha receptor and attenuates its signaling. Pigment Cell Melanoma Res, 23: 838-40.
  • Bhattacharya S, HuangFu WC, Liu J, Veeranki S, Baker DP, Koumenis C, Diehl JA, and Fuchs SY (2010) Inducible priming phosphorylation promotes ligand-independent degradation of the IFNAR1 chain of Type I interferon receptor. J Biol Chem, 285: 2318-25.